Potential of sulfur-selenium isosteric replacement as a strategy for the development of new anti-chagasic drugs

Acta Trop. 2022 Sep:233:106547. doi: 10.1016/j.actatropica.2022.106547. Epub 2022 Jun 3.

Abstract

Current treatment for Chagas disease is based on only two drugs: benznidazole and nifurtimox. Compounds containing sulfur (S) in their structure have shown promising results in vitro and in vivo against Trypanosoma cruzi, the parasite causing Chagas disease. Notably, some reports show that the isosteric replacement of S by selenium (Se) could be an interesting strategy for the development of new compounds for the treatment of Chagas disease. To date, the activity against T. cruzi of three Se- containing groups has been compared with their S counterparts: selenosemicarbazones, selenoquinones, and selenocyanates. More studies are needed to confirm the positive results of Se compounds. Therefore, we have investigated S compounds described in the literature tested against T. cruzi. We focused on those tested in vivo that allowed isosteric replacement to propose their Se counterparts as promising compounds for the future development of new drugs against Chagas disease.

Keywords: Bioisosterism; Chagas disease; In vivo; Selenium; Sulfur; Trypanosoma cruzi.

Publication types

  • Review

MeSH terms

  • Chagas Disease* / drug therapy
  • Chagas Disease* / parasitology
  • Humans
  • Selenium* / therapeutic use
  • Sulfur / therapeutic use
  • Trypanocidal Agents* / chemistry
  • Trypanocidal Agents* / pharmacology
  • Trypanocidal Agents* / therapeutic use
  • Trypanosoma cruzi*

Substances

  • Trypanocidal Agents
  • Sulfur
  • Selenium